Drug intelligence / Profile preview

BMB-105

Development stage: Unknown
Lead developer: Bright Minds Biosciences
Modality: Small Molecules
Administration: Oral

Overview

BMB-105 is a next-generation selective serotonin 5-HT2A/2C receptor agonist developed by Bright Minds Biosciences. It is being investigated for the treatment of neurological and psychiatric disorders, including Prader-Willi Syndrome, absence seizures, and developmental and encephalopathic epilepsies (DEEs). The company plans to initiate a Phase 1 clinical trial for BMB-105.

Targets

HTR2C (5-hydroxytryptamine 2C receptor)

Beyond the preview

Go deeper on BMB-105.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BMB-105.

Explore the full profile